Standard BioTools Inc

NASDAQ: LAB    
Share price (5/17/24): $2.57    
Market cap (5/17/24): $956 million
Search in Documents
Key Exhibits
External Links
9 Standard BioTools Inc Expert Interviews, now on BamSEC.
 Powered by Tegus.

Material Contracts Filter

EX-10.96
from 10-K/A 2 pages Standard BioTools Inc. Nonemployee Director Compensation Policy
12/34/56
EX-10.1
from 8-K 17 pages Exchange Agreement
12/34/56
EX-10.96
from 10-K 3 pages Standard BioTools Inc. Outside Director Equity Compensation Policy
12/34/56
EX-10.2
from 10-K 14 pages Standard BioTools Inc. Indemnification Agreement This Indemnification Agreement (“Agreement”) Is Made as of , 2024 by and Between Standard BioTools Inc., a Delaware Corporation (The “Company”), and [Name] (“Indemnitee”). 1. Definitions
12/34/56
EX-10.1
from 8-K 17 pages Standard BioTools Inc. 2011 Equity Incentive Plan
12/34/56
EX-10.1
from S-4 5 pages October 1, 2023 Term
12/34/56
EX-10.11
from 10-Q 4 pages Appendix a Standard BioTools Inc. 2023 Change of Control and Severance Plan Participation Agreement
12/34/56
EX-10.10
from 10-Q 2 pages April 4, 2022 Compensation
12/34/56
EX-10.9
from 10-Q 4 pages Appendix a Standard BioTools Inc. 2023 Change of Control and Severance Plan Participation Agreement
12/34/56
EX-10.3
from 8-K 9 pages Standard BioTools Inc. 2011 Equity Incentive Plan Performance Unit Award Agreement
12/34/56
EX-10.2
from 8-K 4 pages Appendix a Standard BioTools Inc. 2023 Change of Control and Severance Plan Participation Agreement
12/34/56
EX-10.1
from 8-K 13 pages Standard BioTools Inc. 2023 Change of Control and Severance Plan and Summary Plan Description Adopted August 4, 2023
12/34/56
EX-10.1
from 8-K 17 pages Standard BioTools Inc. 2011 Equity Incentive Plan
12/34/56
EX-10.3
from 8-K 15 pages May 10, 2023 This Letter Agreement (This “Agreement”) Sets Forth the Terms and Conditions Relating to Certain Benefits That You May Become Eligible to Receive in the Event of Your Termination of Employment From Standard BioTools Inc. (The “Company”). for Valuation Consideration, the Receipt and Sufficiency of Which Are Hereby Acknowledged, and Intending to Be Legally Bound Hereby, the Company and You Hereby Agree as Follows
12/34/56
EX-10.2
from 8-K 4 pages Appendix a Standard BioTools Inc. 2020 Change of Control and Severance Plan Participation Agreement
12/34/56
EX-10.1
from 8-K 3 pages Join an Innovative Team Driven by a Bold Vision – Unleashing Tools to Accelerate Breakthroughs in Human Health May 9, 2023
12/34/56
EX-10.1
from 10-Q 16 pages Material contract
12/34/56
EX-10.32
from 10-K 15 pages Material contract
12/34/56
EX-10.1
from 10-Q 16 pages This Sublease (This “Sublease”) Is Dated for Reference Purposes as of August 30, 2022, and Is Made by and Between Standard BioTools Inc., a Delaware Corporation (Formerly Known as Fluidigm Corporation) (“Sublessor”), and Circ Bio, Inc., a Delaware Corporation (“Sublessee”). Sublessor and Sublessee Hereby Agree as Follows
12/34/56
EX-10.1
from 8-K 8 pages March 29, 2022 Caligan Partners LP 590 Madison Avenue New York, New York 10022 Attn: David Johnson Ladies and Gentlemen
12/34/56